FDA advances testosterone label
The FDA advanced a testosterone therapy targeted at men with idiopathic hypogonadism and low libido, specifying the indication rather than broader sexual‑function claims. (x.com) Regulatory notes framed the move as focused on that clinical diagnosis rather than general use for aging‑related libido changes. (x.com)
The Food and Drug Administration said on April 16, 2026, that it is opening a path for testosterone drugs to seek approval for low libido in men with idiopathic hypogonadism. (fda.gov) The agency did not approve a new use on Thursday. It asked holders of approved testosterone replacement therapy new drug applications to contact the agency by April 30, 2026, if they want to file supplemental applications for that indication. (fda.gov) (federalregister.gov) Idiopathic hypogonadism means persistently low testosterone without a known structural or genetic cause. The Federal Register notice says the possible new use is limited to men with decreased libido associated with that diagnosis. (federalregister.gov) Testosterone therapy is already sold in oral, topical, patch, buccal, and injectable forms, but current Food and Drug Administration labeling limits approved use to men with hypogonadism linked to recognized medical conditions. The agency said those products are not approved for ordinary aging-related testosterone decline. (fda.gov 1) (fda.gov 2) The new step follows a December 10, 2025, Food and Drug Administration expert panel on testosterone replacement therapy for men. The agency said its preliminary review of published, well-controlled trials and that panel discussion suggested testosterone may help some men with low libido tied to idiopathic hypogonadism. (fda.gov 1) (fda.gov 2) The Food and Drug Administration also said any label expansion would still require substantial evidence that the drugs work and that benefits outweigh risks in the intended population. That keeps the decision in the usual supplemental new drug application process rather than a blanket policy change for the whole class. (fda.gov) That caution reflects the agency’s recent rewrite of testosterone labels. In February 2025, the Food and Drug Administration removed a boxed warning about increased cardiovascular risk after the TRAVERSE trial, but kept limitations for age-related hypogonadism and added blood-pressure warnings across the class. (fda.gov) Current labels show the tradeoff clearly. For example, TLANDO, an oral testosterone product, says testosterone levels must be confirmed with morning blood tests on two separate days before treatment, and its label warns about polycythemia, venous thromboembolism, prostate monitoring, and blood-pressure increases. (accessdata.fda.gov) So the immediate change is procedural, not clinical: drugmakers now have a defined opening to ask for a narrower libido indication tied to a diagnosed hormone disorder. Whether any testosterone product actually wins that label will depend on the data sponsors bring to the Food and Drug Administration next. (fda.gov) (federalregister.gov)
